Clinical Guidelines
Feature

EYP-1901 for Retinal Exudative Diseases

An overview of the current status of the EYP-1901 clinical trial program in wet AMD and DME, presented at Hawaiian Eye and Retina 2026

Share

EYP-1901, an investigational intravitreal insert, aims to address the high treatment burden of wet age-related macular degeneration (AMD) and diabetic macular edema (DME) with sustained release of the tyrosine kinase inhibitor vorolanib. Early clinical trials (DAVIO 1 and 2) indicate that EYP-1901 demonstrates statistical noninferiority to aflibercept, significantly reducing the need for additional treatments. Ongoing Phase 3 trials, LUGANO and LUCIA, aim to further establish its safety and efficacy, with results expected by mid-2026.

Original Source(s)

EYP-1901 for Retinal Exudative Diseases

An overview of the current status of the EYP-1901 clinical trial program in wet AMD and DME, presented at Hawaiian Eye and Retina 2026

  • by Sumit Sharma

  • January 23, 2026

  • 5 min

Related Content

When the Kidney Meets the Retina

New study suggests potential causal link between kidney disease and AMD

  • January 22, 2026

  • 3 min
Coding Q&A: Coding Guidelines for Wet AMD

Proper use of ICD-10-CM codes ensures compliance and prompt payment.

Video: Reducing Injections in Wet AMD

Avni Finn, MD, and Diana V. Do, MD, discuss promising results from the DAVIO2 trial of EYP-1901.